Envista (NYSE:NVST) had its target price boosted by analysts at Piper Sandler from $45.00 to $47.00 in a research note issued on Wednesday, The Fly reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s price target indicates a potential upside of 7.35% from the company’s current price.
Several other equities analysts have also issued reports on NVST. Morgan Stanley lifted their price target on Envista from $42.00 to $46.00 and gave the stock an “equal weight” rating in a research report on Friday, May 7th. Credit Suisse Group lifted their price target on Envista from $49.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, May 6th. Zacks Investment Research raised Envista from a “hold” rating to a “strong-buy” rating and set a $52.00 price target for the company in a research report on Saturday, May 8th. Finally, TheStreet raised Envista from a “d+” rating to a “c” rating in a research report on Thursday, May 13th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $43.67.
Shares of NVST stock opened at $43.78 on Wednesday. The business has a fifty day simple moving average of $42.95. Envista has a 52 week low of $22.00 and a 52 week high of $46.52. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of 64.38, a price-to-earnings-growth ratio of 0.86 and a beta of 1.93. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.02 and a quick ratio of 0.77.
Envista (NYSE:NVST) last announced its quarterly earnings data on Tuesday, August 3rd. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.44 by $0.09. Envista had a return on equity of 6.93% and a net margin of 5.00%. As a group, research analysts predict that Envista will post 1.9 EPS for the current year.
In other Envista news, SVP Jeffrey Kappler sold 1,717 shares of the company’s stock in a transaction on Friday, July 16th. The stock was sold at an average price of $42.00, for a total value of $72,114.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Howard H. Yu sold 35,021 shares of the company’s stock in a transaction on Friday, May 7th. The shares were sold at an average price of $45.17, for a total value of $1,581,898.57. Following the completion of the transaction, the chief financial officer now directly owns 66,297 shares in the company, valued at approximately $2,994,635.49. The disclosure for this sale can be found here. Over the last three months, insiders sold 74,862 shares of company stock worth $3,317,082. 0.82% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of NVST. Schroder Investment Management Group raised its stake in Envista by 7.3% in the fourth quarter. Schroder Investment Management Group now owns 1,502,310 shares of the company’s stock valued at $50,673,000 after buying an additional 102,626 shares during the last quarter. Canada Pension Plan Investment Board raised its stake in Envista by 164,510.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 16,461 shares of the company’s stock valued at $555,000 after buying an additional 16,451 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Envista in the fourth quarter valued at about $394,000. Truist Financial Corp purchased a new stake in Envista in the fourth quarter valued at about $761,000. Finally, Dimensional Fund Advisors LP raised its stake in Envista by 11.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,683,495 shares of the company’s stock valued at $124,240,000 after buying an additional 378,540 shares during the last quarter.
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Further Reading: Stop Order Uses For Individual Investors
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Envista, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Envista wasn’t on the list.
While Envista currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.